Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.56, for a total transaction of $210,720.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Samuel Kintz also recently made the following trade(s):
- On Thursday, January 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.69, for a total value of $188,280.00.
Enliven Therapeutics Trading Up 5.8 %
Shares of Enliven Therapeutics stock opened at $18.63 on Thursday. The business’s fifty day simple moving average is $15.83 and its 200 day simple moving average is $13.84. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $24.22.
Hedge Funds Weigh In On Enliven Therapeutics
About Enliven Therapeutics
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
- Five stocks we like better than Enliven Therapeutics
- Options Trading – Understanding Strike Price
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Most active stocks: Dollar volume vs share volume
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- What is the FTSE 100 index?
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.